It is currently Fri Jun 24, 2016 6:47 pm

News News of Tcelna (Tovaxin)

Site map of Tcelna (Tovaxin) » Forum : Tcelna (Tovaxin)

A board to discuss Tcelna as a treatment for Multiple Sclerosis

Opexa Presentation at Vatican

Opexa Therapeutics, Inc., announced that its president and chief executive officer, Neil K. Warma, recently gave a presentation on immunotherapy and its potential for treating autoimmune disorders, including multiple sclerosis, at the recent Cellular Horizons:
The Third International Conference on the Progress of Regenerative Medicine and its Cultural Impact held at the Vatican.

Here is the link of the video: ... fault.aspx
Read more : Opexa Presentation at Vatican | Views : 443 | Replies : 0

SPMS Trial?

Does anyone know what's going on with Opexa's phase II trial for SPMS? Their stock has seen some recent activity, but it's been under $1/share since November 1, 2014. They're required to be over $1 in order to stay listed on the NASDAQ. Unless they can pull the proverbial rabbit out of a hat, I predict yet another reverse split is on the way.
Read more : SPMS Trial? | Views : 1652 | Replies : 2

‘Personalised’ treatment results due next year

After the Phase 2b clinical trial achieved full enrolment with 190 secondary progress multiple sclerosis (SPMS) patients, Texas-based Opexa Therapeutics is now awaiting results for the company’s lead candidate, Tcelna, which are expected in the second half of 2016..... Read More -
Read more : ‘Personalised’ treatment results due next year | Views : 1037 | Replies : 0

Opexa news: NMO

It looks like Opexa is working on a treatment for Neuromyelitis Optica. ... fault.aspx
Read more : Opexa news: NMO | Views : 1485 | Replies : 0

Merck Serono Enter into Option and License for Tcelna

Opexa Therapeutics Inc. (OPXA) granted an exclusive license option to Germany-based Merck KGaA's (MKGAY, MRK.XE) biopharmaceutical division for the development and commercialization of Opexa's lead product candidate, Tcelna, for multiple sclerosis in a deal potentially valued at $225 million

They must see something of value?!?! ... 08051.html
Read more : Merck Serono Enter into Option and License for Tcelna | Views : 1973 | Replies : 2

Opexa reverse split

As I had predicted almost a year ago, on December 14th Opexa executed another reverse split. This time it was 1:4. Since then, their stock has fallen an additional 35.2% in value. This does not seem to put them in a good position for their ongoing trial of Tovaxin (Tcelna) with SPMS. ... cle=121412

Read more : Opexa reverse split | Views : 2033 | Replies : 0

Tcelna Trial for SPMS

Hello all. I am new to this forum. I was diagnosed with MS in 1999, and was able to work as a physician until last year. (Irony of Ironies...physician heal thyself!). I am looking to see whether I am a candidate to get on the Tcelna trial. Has anyone here already been selected? It is a double blind study, so what happens to those that end up in the placebo control group? In some studies, ...
Read more : Tcelna Trial for SPMS | Views : 12309 | Replies : 34

Recruiting Locations for TCelna (Tovaxin)

Looks like they at least have locations and some are even recruiting: ... exa&rank=3
Read more : Recruiting Locations for TCelna (Tovaxin) | Views : 2457 | Replies : 1

TCELNA 11B trial will start recruiting for the Abili-T trial

Drug previously know as "Tovaxin". Sounds like some patients have already been enrolled, and they are expecting to enroll more SPMS patients. I hope it turns out to be as promising as it sounds. ... 00862.html ... on=tovaxin
Read more : TCELNA 11B trial will start recruiting for the Abili-T trial | Views : 2267 | Replies : 0

Double barrel approach

So I understand that Tovaxin has been designed to work, by targeting T-Cells specifically involved in attacking Myelin. Now, on the other hand we have another treatment called Campath, which has shown some positive effectiveness by targeting CD52, a protein present on the surface of mature lymphocytes. I would think that the scientists would somehow also be able to train Tovaxin to also target CD52 as well as its current targets, and thereby combine the ...
Read more : Double barrel approach | Views : 1962 | Replies : 0


Login  •  Register


Total posts 232909 • Total topics 24939 • Total members 16075

Contact us | Terms of Service